Lemonade is light years ahead of competitors in agentic insurance as policies shift from set-and-forget to hundreds of micro-interactions each year. It is the first company to truly enter this model while incumbents still work on AI premium-pricing models. Pet insurance involves frequent small claims, and car telematics keeps updating driving-based prices and safety assessments. x.com 

Tesla's growing autonomy usage strengthens its case as one of the best plays on autonomous vehicles, robotics, EVs and energy. Q3 FSD subscriptions rose 67% year over year and robotaxi miles increased eightfold quarter over quarter; revenue was $28.05B and EPS of $0.48 beat expectations. FSD subscriptions are starting to contribute to revenue, though still relatively little. Licensing FSD to other automakers could expand the opportunity if it happens. x.com  x.com 

Lemonade looks good but not good enough after a lofty price and high expectations into earnings, so it needs to get cheaper before it is worth buying. In-force premium grew 32% and revenue 79% as it approaches positive cash flow by the end of 2026; the low $40s or $30s would be the level to buy more. x.com  x.com 

Lemonade's share-price drop after a great second quarter is a wild overreaction. Per its Q2 2026 results, in-force premium rose 32.4% to $1.43 billion and revenue grew 79% to $294 million, the 11th straight quarter of accelerating growth, with over 3.3 million customers. x.com  x.com 

Tesla's FSD continues to drive sales as its physical AI strategy takes shape. Attach rates top 75% of North American deliveries, active subscriptions have reached 1.74 million, up 67% year on year, and Optimus production has begun. Those developments also dovetail with the strategic fit of a SpaceX merger. x.com 

Self-driving cars give Root and Lemonade no edge, because if accidents fall, everyone benefits and insurers charge less, so the whole auto insurance industry shrinks. On the surface the risk looks like self-driving's threat to Uber, but the mechanics are completely different, and insurance companies are not attractive to own in general. The view is offered tentatively, as a non-expert. x.com  x.com 

Lemonade and Tempus AI are where AI returns become visible, as capital moves from infrastructure up to the application layer. Big Tech's hundreds of billions in AI capex still show little attributable revenue and no clear moat beyond scale, and infrastructure depreciates. Lemonade's marketing buys customer relationships that can last decades and improve underwriting; Tempus's clinical dataset grows harder to replicate with each patient, backing pharma revenue with 126% NRR. x.com 

Tesla's growing FSD subscriber base supports the longer-term autonomy case, but the AI build is taxing cash now. Paid FSD seats reached about 1.74 million, up 67%, while free cash flow fell 62% to $1.53 billion despite an EPS and sales beat. Post-report weakness is a discount discussion only for holders able to weather another weak cash quarter; check FSD net adds and FCF before leaning hard. A possible SpaceX combination is not part of this case. x.com 

Lemonade looks expensive once valued as what it is, an insurance company. Replying to @javierluraschi's post on the stock, any price above 1x revenue is expensive for an insurer. x.com 

Tesla's FSD uptake could add recurring software revenue to its vehicle base, while Robotaxi could earn on each ride. This could be Tesla's most important inflection point, missed amid weak auto profits. North American attach rates rose to 75% from 55% in Q2; subscriptions hit 1.74 million, up 67% year over year, and Cybercab rides began in Austin. Trials may not become lasting paid subscriptions; Robotaxi needs safe operation, steady paying demand and attractive returns at scale. x.com